Arch Therapeutics

Arch Therapeutics

Biotechnology, 235 Walnut St, Framingham, Massachusetts, 01702, United States, 11-50 Employees

archtherapeutics.com

  • twitter
  • LinkedIn

phone no Phone Number: +19*********

Who is ARCH THERAPEUTICS

Arch Therapeutics, Inc. (OTCQB:ARTH) is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trau...

Read More

map
  • 235 Walnut St, Framingham, Massachusetts, 01702, United States Headquarters: 235 Walnut St, Framingham, Massachusetts, 01702, United States
  • 2006 Date Founded: 2006
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 3841

checked-icon Does something look wrong? Fix it. | View contact records from ARCH THERAPEUTICS

Arch Therapeutics Org Chart and Mapping

Employees

Richard Davis

Chief Financial Officer

Dan Yrigoyen

Senior Vice President, Sales & Marketing

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Arch Therapeutics

Answer: Arch Therapeutics's headquarters are located at 235 Walnut St, Framingham, Massachusetts, 01702, United States

Answer: Arch Therapeutics's phone number is +19*********

Answer: Arch Therapeutics's official website is https://archtherapeutics.com

Answer: Arch Therapeutics's revenue is $5 Million to $10 Million

Answer: Arch Therapeutics's SIC: 3841

Answer: Arch Therapeutics has 11-50 employees

Answer: Arch Therapeutics is in Biotechnology

Answer: Arch Therapeutics contact info: Phone number: +19********* Website: https://archtherapeutics.com

Answer: Arch Therapeutics, Inc. (OTCQB:ARTH) is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5 Advanced Wound System and AC5 Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-GTM, AC5-V and AC5 Surgical Hemostat, among others.1,2 1 AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use. 2 AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access